Introduction
Negative symptoms have long been defined as a key aspect of schizophrenia, they are often resistant to common treatments and severely interfere with functional outcome of subjects with the disorder. [1] [2] [3] [4] [5] [6] [7] The National Institute of Mental Health treatment-oriented consensus statement 2 of 2006 included 5 core domains of negative symptoms: blunted affect, poverty of speech (alogia), avolition or amotivation, anhedonia, and asociality. 3, 8 Factor analyses showed that both broadly defined 1, [9] [10] [11] [12] and primary and enduring [13] [14] [15] [16] negative symptoms cluster in 2 separate factors, the motivation-related domain of Avolition/apathy (including avolition, asociality, and anhedonia) and the expression-related domain of Expressive deficit (including blunted affect and alogia). The 2 domains are associated to different neurobiological abnormalities and have a different impact on functional outcome. [17] [18] [19] [20] Galderisi et al 16 reported longitudinal stability of the 2 negative factors in chronic patients with schizophrenia and showed that Avolition/apathy was more predictive of poor psychosocial outcome than Expressive deficit. Several other studies confirmed that the Avolition/apathy factor is a stronger predictor of functional outcome than the Expressive deficit one. 5, 16, 19, 21, 22 predictors of real-life functioning. 5, 24, 25 The relationships between cognitive and motivational deficits in schizophrenia are currently debated. [26] [27] [28] [29] [30] National Institute of Mental health (NIMH) Research Domain Criteria (RDoC) constructs include 2 relevant pathways: the hedonic and the cognitive pathways, which, according to authors, 30 can both lead to motivation-related negative symptoms.
Several studies reported, in subjects with schizophrenia, a disturbance in cognitive control, defined as the ability to guide and adjust flexibly cognitive processes and behavior in accordance with one's intentions and goals. [31] [32] [33] Some studies have tried to characterize the interaction between motivation and cognitive control 34, 35 reporting that motivation can reduce response conflict 36 and improve task performance. 37 In subjects with schizophrenia an impairment in motivational processes, especially in the valuation of action and formation of action-outcome associations to guide behavior, 38, 39 prevents the positive effect of motivation on cognitive control. In fact, in these subjects, incentives do not increase cognitive activation and do not favor cognitive control strategies, as observed in healthy individuals. [40] [41] [42] Neuroimaging studies and event-related brain potentials (ERPs) research on cognitive control have identified the central role of the anterior cingulate cortex (ACC). Its activity is reflected in the frontocentral ERP N2 component, a negative wave peaking between 200 and 350 ms after stimulus onset. [43] [44] [45] [46] [47] [48] [49] [50] The ACC is engaged in monitoring behavioral outcome (for error detection), selecting reward-based actions 51, 52 and implementing the executive control (ie, inhibition of response when not appropriate, correction and implementation of new behavioral responses to face a problem). 53, 54 The N2 was found to reflect several aspects of cognitive control, such as response inhibition, 55 as well as conflict detection/resolution 56 and error monitoring. 57 Several findings indicated an effect of incentives on N2 amplitude in healthy controls. In fact, the N2 for cues predictive of subsequent outcomes is more negative for those anticipating unfavorable outcomes (eg, monetary loss), and more positive for those anticipating a reward (eg, monetary win). [58] [59] [60] [61] Pornpattananangkul and Nusslock 62 corroborated these findings during reward/no-reward cue-evaluation, observing that reward-anticipation cue led to a smaller N2 amplitude. Potts 63 found that reward stimuli elicited a less negative N2 than punishment stimuli (which signaled the possibility of losing money if performance failed to meet accuracy standards).
A highly influential experimental paradigm, that is designed to explicitly separate neural activity elicited by reward and loss anticipation and outcome, is the monetary incentive delay (MID) task, 64 often used in fMRI investigations in people with schizophrenia. [65] [66] [67] [68] [69] The MID task involves the presentation of incentive cues (predicting reward or loss) and neutral ones (predicting no outcome), followed by a delay period (anticipation phase); then, the presentation of a target to which the subject has to provide a response (response phase) to gain the anticipated monetary reward or to avoid the anticipated loss of money, and finally the presentation of a feedback on gain or loss (outcome phase). Novak and Foti 61 evaluated cue-N2 data recorded during an adapted version of the MID task, and showed that the cue-N2 was more negative for unfavorable anticipation conditions (potential loss) and more positive for favorable ones (potential win). In a further experiment, the authors modified the trial structure by presenting only 2 cues: one related to monetary incentive and one to neutral outcome, observing that cue-N2 amplitude was significantly increased for incentive compared with neutral trials. 61 In schizophrenia, many studies have shown abnormal structure and function of ACC 70, 71 and reduced amplitude and prolonged latency of N2. [72] [73] [74] [75] [76] [77] Some studies showed that N2 amplitude changes were correlated with illness duration 76, 78 but not with negative symptoms. 79, 80 To our knowledge, no previous study has examined the impact of reward-and avoidance-based motivation on N2 in a sample of subjects with schizophrenia.
The aim our study was two-fold: (1) to investigate the effects of reward and loss avoidance anticipation on N2, using a MID task paradigm in subjects with schizophrenia and healthy controls and (2) to evaluate the relationships of N2 with Avolition/ apathy and cognitive domains, assessed using the MATRICS Consensus Cognitive Battery (MCCB 81 ).
Materials and Methods

Participants
The study participants included 25 healthy controls (HC) and 38 subjects with schizophrenia (SCZ) as in our previous study.
82
SCZ were recruited from outpatient units of the University Psychiatric Department of Naples between September 2010 and July 2012. Inclusion criteria were: (1) a clinical diagnosis of schizophrenia confirmed using the Mini International Neuropsychiatric Interview-Plus (MINI-Plus); (2) age between 18 and 65 years; (3) clinically stable (ie, no hospitalization or change in psychotropic medication for 3 months prior to recording), to avoid the presence of severe positive symptoms, which might cause secondary negative symptoms; (4) treatment with second-generation antipsychotics (SGAs) only; (5) a negative neurological examination; (6) a negative history of moderate mental retardation, neurological illness, head injury with loss of consciousness, alcoholism or drug abuse or dependence in the past 6 months (except for smoking); and (7) no previous insulin coma, leucotomy, or electroconvulsive therapy. HC matched with SCZ for age (±3 years), gender, and handedness were recruited from the community. They were excluded if they had a past or a current DSM-IV Axis I disorder based on MINI-Plus interview or a family history of affective or psychotic disorders. Additionally, exclusion criteria included major medical illnesses, history of seizures, history of head injury resulting in a loss of consciousness, neurological illness, mental retardation, lifetime history of substance abuse or dependence (except for smoking), and the use of drugs that might affect central nervous system functions (eg, hormones). The assessment of the handedness was carried out by the Edinburgh Inventory. 83 All subjects had normal or corrected to normal vision. A neurophysiological evaluation was carried out in all enrolled subjects.
Ethics Committee of the Medical Hospital of the Second University of Naples approved the study. All subjects provided a written informed consent, after a complete description of the study.
Assessments
All subjects were evaluated for sociodemographic variables such as age, gender, and parental education. General cognitive abilities, as total intelligence quotient (TIQ) were assessed using the Wechsler Adult Intelligence Scale-Revised (WAIS-R). Measures of Avolition/apathy and Expressive deficit were extracted from Schedule for the Deficit Syndrome (SDS 84 ). Avolition/apathy was computed by summing the scores on the items Curbing of Interests, Diminished Sense of Purpose, and Diminished Social Drive. Expressive deficit was calculated by summing the scores on the items Restricted Affect, Diminished Emotional Range, and Poverty of Speech. 16, 84 Subjects were also administered the Positive and Negative Syndrome Scale (PANSS 85 ) to assess positive, disorganization, and depression dimensions. 86 Neurocognitive functions were rated using MCCB. 81 This battery includes tests for the assessment of 7 distinct cognitive domains such as processing speed, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. For all the cognitive domains, T-scores as well as a neurocognitive composite score, were calculated by the MCCB Scoring Program, through a correction of the raw scores by age and gender. The daily antipsychotic dose on the day of recording was converted to chlorpromazine equivalents following Gardner et al. 87 
Experimental Design
As described in our previous study, 82 we used a modified version of the MID task. 64 In this task, the subjects have to press a button within a predefined time window to win or avoid losing money. There were 4 incentive conditions-large reward, small reward, large loss, and small loss-and a neutral condition, presented in random order. The proportion of trials for the incentive conditions (18 trials each) and for the neutral one (24 trials) was the same as in the original MID task. After cue presentation (250 ms), subjects waited a variable interval (delay; 2000-2500 ms) and then had to respond to a white target square that appeared for a variable length of time by pressing a button with the index finger of their dominant hand. After target presentation, a feedback appeared (1650 ms), notifying subjects whether they won or did not win money on reward trials, or whether they lost or did not lose money on the loss trials.
A total of 96 trials, each with duration of 6 seconds, were completed with total task duration of 9.6 minutes.
Task difficulty, related to the duration of target exposure, was based on reaction times collected during a previous 48 trial practice session. During practice session, subjects were instructed to press the button as fast as possible irrespective of the cue type and were excluded from analysis if they achieved less than 60% of correct responses.
Subjects were also informed about the amount of money that they could earn when the task was successfully performed, and, after the EEG acquisition, participants were paid the amount of money they won.
For both tasks, stimuli presentations and recording of reaction times were performed using the software Presentation (Neurobehavioral Systems, Inc).
Data Acquisition and Preprocessing
EEG was recorded with a 32-channel digital EEG system EASYS2 (Brainscope, Prague) using a cap electrode system with 30 unipolar leads (Fpz, Fz, Cz, CPz, Pz, Oz, F3, F4, C3, C4, FC5, FC6, P3, P4, CP5, CP6, O1, O2, Fp1, Fp2, F7, F8, T3, T4, T5, T6, AF3, AF4, PO7, PO8), placed following the 10-20 system (American Electroencephalographic Society). All the leads were referenced to the linked earlobes (a resistor of 10 kohm was interposed between the earlobe leads). A ground electrode was placed on the forehead. A horizontal electro-oculogram (hEOG) was recorded from the epicanthus of each eye, and a vertical EOG (vEOG) from the leads beneath and above the right eye for artifact monitoring. All impedances of the leads were kept less than 5 kohm. The EEG data were filtered with a band-pass of 0.1-70 Hz and recorded with a sampling rate of 256 Hz. A calibration was performed for all channels, using a 50 μV sine wave, before each recording session. Subjects were instructed to relax, maintain a constant level of attention throughout the whole session, and avoid movements during the recording. Smokers were allowed to smoke prior to EEG recording (last cigarette approximately 60 minutes before session) to avoid the potential effects of nicotine withdrawal. All subjects were instructed to abstain from coffee and tea for at least 12 hours overnight before the next morning's experiment and to consume a light breakfast. EEG was recorded at about 9.00 am in all subjects. EEG data were analyzed using Brain Vision Analyzer software 2.0 (Brain Vision, Germany). The EEG was digitally filtered off-line with a 1-15-Hz band-pass. The eye movements were corrected using independent component analysis. 88 Independent component analysis corresponding to artefactual sources and brain activity were separated with a manual procedure.
Data Analysis
Event-Related Potentials. Epochs were time-locked to the onset of the cue, including a 200 ms pre-stimulus period, and extended to 1500 ms post-stimulus presentation. Baseline correction (using the 100 ms before stimulus onset as reference) was performed for all segments.
ERP averages were based on a minimum of 50% of the total trials for each cue type. ERP averages for all 5 conditions (small and large potential monetary reward, small and large potential monetary loss, and neutral outcome) were calculated for each participant.
In accordance with previous N2 studies, 48, 57, 61 the baselineto-peak N2 amplitude was evaluated as the most negative peak occurring between 220 and 320 ms after stimulus presentation at Fz lead. 57 Statistical Analyses. Data distributions were examined for normality and homogeneity of variance. Outliers (subjects whose scores exceeded the 75th or the 25th percentile by 1.5 times the interquartile range) were excluded from the analysis. 89 Group differences in gender distribution was assessed by the Pearson's chi-square test. Analysis of variance (ANOVA) was used to test group differences on continuous variables. LSD (least significant difference) procedure was used for post hoc comparisons.
For group differences, a repeated-measure of variance (ANOVA) was designed with Diagnosis as the between-subjects factor and N2 amplitude or latency for all cue types as dependent variables.
The effect of the cue type on N2 mean amplitude was assessed by repeated-measure ANOVA in each group, with Cue as a within-subjects factor.
The Greenhouse-Geisser correction for the violation of sphericity was applied when appropriate.
Reaction time (in milliseconds) was analyzed using repeated measures analysis of covariance (ANCOVA), with all cue reaction times as the within-subjects factor, diagnosis as the between-subjects factor, and WAIS Total Intelligence Quotient (TIQ) as covariate.
Correlations between N2 amplitude and TIQ and psychopathological dimensions were explored by means of Pearson's correlation test. A Bonferroni correction was applied to avoid type 1 error for multiple tests. Statistical significance level was set at P ≤ .05 for all tests.
All analyses were carried out using SPSS 22 (IBM Corp, Armonk, NY).
Results
One subject with SCZ and 2 HCs were excluded because they were unable to perform the target identification task during ERP recording (they achieved less than 60% of correct responses). One subject with SCZ was excluded for low IQ and task performance. Since, none of the included SCZ had a positive history of intellectual disability. One subject with SCZ was excluded for the presence of artifacts in the ERP recordings (less than 9 trials were available for averaging). One SCZ and one HC resulted to be outlier for N2 amplitude measures.
Thus, the final study sample consisted of 34 SCZ and 22 HC.
Demographic Data and Behavioral Results
There was no group difference in age and parental education (Table 1) . We observed a significant difference in the gender between HC and SCZ by the χ 2 test (P = .048; Table 1 ). SCZ sample included significantly more male than HC. SCZ had significantly lower TIQ than HC and the 2 groups differed significantly on all MATRICS domains (Table 1) . For SCZ, clinical information is reported in Table 1 .
ANOVAs with cue as the within-subject variable were performed to examine reaction time in HC and SCZ groups.
A main effect of the cue was found only in the healthy controls (F 4, 84 = 2.84, P < .045). Reaction time was shorter for large reward cues compared with small reward (P < .008) or neutral cues (P < .003).
In SCZ, the main effect of the cue was not found (F 4, 132 = 0.21, P = .904).
A 5 (cue) × 2 (group) ANCOVA showed no significant main effect of diagnosis on reaction time (F 1, 53 = 3.00, P = .089).
N2 Findings
A 5 (cue) × 2 (group) repeated-measures ANOVA revealed no significant differences between groups for N2 amplitude (F 1, 54 = 2.22; P = .144) and latency (F 1, 54 = 0.44; P = .510). In the HC group, a significant main effect of the cue on N2 amplitude was found (F 4, 84 = 4.80; P < .004). Post hoc pairwise comparisons showed significantly larger amplitude for large loss compared to small reward (P < .037), large reward (P < .039), and neutral (P < .0001). A smaller amplitude for neutral compared with small reward (P < .026), small loss (P < .035), large loss (P < .0001), and large reward (P < .013) was observed ( Figure 1A ).
In the SCZ group, no main effect of the cue on N2 amplitude was found (F 4, 132 = 1.71; P = .281) ( Figure 1B) . As a control analysis, we included TIQ and gender as covariates and we did not have any main effect on N2 amplitude ( 
Correlation Analysis
N2 amplitude was not associated with FSIQ and MCCB domain scores in either group.
No significant correlation was found between the psychopathological indices and N2 amplitude measures in SCZ.
Discussion
The present study aimed to investigate the N2, an ERP index of cognitive control, during the reward-and loss avoidance anticipation, in a sample of chronic, stabilized subjects with schizophrenia, treated with SGAs only. The study also aimed to explore the relationships of N2, during incentive conditions, with Avolition/apathy and Expressive deficit domains of negative symptoms, as well as with MCCB cognitive domains. Rectangles denote the time window. LR, large reward; SR, small reward; LL, large loss; SL, small loss; NE, neutral condition. *Significant larger amplitude for LL versus SR (P < .04), LR (P < .04), and NE (P < .0001). #Significant smaller amplitude for NE versus SR (P < .03), SL (P < .03), LL (P < .0001), and LR (P < .01).
Main results of our study included: (1) a significant effect of incentives on N2 amplitude, with increased amplitude for loss with regard to reward anticipation and for all incentive conditions with respect to neutral one, in healthy controls; (2) no effect of incentives on N2 amplitude in SCZ; (3) no group difference in N2 amplitude and latency; and (4) no association of N2 amplitude with Avolition/apathy or Expressive deficit and other psychopathological or cognitive domains.
Consistent with previous studies, we observed that cue-N2 amplitude differentiated between potential loss or reward anticipation. 61, 63, 90 Similar to the findings by Novak and Foti, 61 we found, in HC, that the N2 amplitude was more negative for unfavorable potential outcomes (potential loss cues) and more positive for favorable ones (potential win cues) and was significantly increased for incentive compared to neutral trials. These findings suggest that cognitive control marks the relevance of future events in terms of stimulus valence and salience.
The use in our experimental paradigm of reward, neutral and loss-anticipation conditions, allowed us to test the theory that reward-anticipation cues could affect the N2 via a template mismatch mechanism. 57, 62 Specifically, it has been hypothesized that subjects may expect reward-anticipation cues to be more frequent than loss-anticipation ones. Thus, enhanced N2 to the loss-anticipation cue may reflect a mismatch with subjects' expectations. The hypothesis is in line with several findings showing that unpredicted or improbable outcomes elicit larger N2 amplitude than the expected outcome. [91] [92] [93] In line with the mismatch theory, we observed a more negative N2 to loss-than reward-anticipation cues. 62 However, the comparison of reward-anticipation cues with neutral cues argues against this theory. In fact, we observed a larger N2 for reward than neutral cues, while the mismatch hypothesis predicts larger amplitude for all non-reward-anticipation cues, including the neutral ones.
Our findings may be interpreted in the frame of enhanced cognitive control when anticipating loss, 63, 90 but extend the findings to anticipation of all incentive conditions. Our data suggest that incentive cues predicting motivationally salient stimuli (both negative or positive) are associated with enhanced cognitive control processes, indexed by the N2 amplitude.
Unlike what was observed in HC, in our study, motivational incentives did not enhance N2 amplitude in subjects with SCZ, indicating an impairment in the interaction of motivation and cognitive control processes, in line with several other findings. 94, 95 The impaired sensitivity to motivational salient stimuli in schizophrenia could explain in part the difficulties of affected subjects to initiate and persist in goal-directed behavior in real life. However, the N2 amplitude did not correlate with Avolition/ apathy, suggesting that this negative symptom domain is related to different aspects of impaired motivational processes. As a matter of fact, recent conceptualizations of motivation distinguish between different processes subserved by partially interconnected dopaminergic circuits: the motivational value system (corresponding to the NIMH RDoC Positive valence system) and the motivational salience system. 96 In the latter system, the striatum has extended connections with dorsolateral and ventrolateral prefrontal cortex and is involved in general motivation to act, cognitive activation and orienting to salient stimuli. N2 amplitude might be the electrophysiological correlate of the interaction of the latter processes with cognitive control. Avolition/apathy might be related to processes of impaired valuation and integration of value and action selection, subtended by the NIMH RDoC positive valence system, as indicated by our own 67 and literature data. 38 Our findings are in line with the results of Stefánsson and Jónsdóttir 79 and Higashima et al, 80 who also did not find any association between the negative symptoms and N2 amplitude or latency.
The lack of associations of N2 amplitude with other psychopathological dimensions, MCCB cognitive domains or general cognitive abilities (as assessed by WAIS TIQ) suggests that the reduced sensitivity to motivational salience is independent of cognitive deficits and psychopathology. Future studies in first episode and high-risk subjects might clarify whether the reduced sensitivity to motivational salience is a trait marker.
In our study, the frontal N2 amplitude was not reduced in subjects with SCZ with regard to HC, in contrast with previous findings in first episode and chronic SCZ subjects for both auditory 73,97-100 and visual modalities. 101, 102 In these studies, included subjects with SCZ were either unmedicated 74, 99 or medicated with first-generation antipsychotics, 73, 75, 97, 100, 101 while in our study they were stabilized on SGAs only. Whether this difference might explain the lack of group effects on N2 amplitude is not clear. Some authors have hypothesized that SGAs with their fast dissociation from D2 receptors and low rate of extrapyramidal side effects might be less detrimental on striatal activity as shown for the motivational value system. 65, 66, 68, 69 Only longitudinal studies might clarify whether SGAs improves the N2 response.
A limitation of our study is the imbalance in gender distribution between the 2 groups and the low TIQ of SCZ. However, we did not find any main effect or interaction of these 2 variables on N2 measures. Furthermore, we investigated the correlations between the N2 measures and TIQ and did not find any significant effect. In the light of these observations, it seems unlike that our findings are confounded by the gender imbalance or differences in TIQ.
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